survodutide 10mg

Survodutide is an investigational dual-receptor co-agonist peptide engineered to activate glucagon receptors and additional metabolic signaling pathways, facilitating complex metabolic regulation in non-human test subjects. Its molecular design optimizes receptor-binding affinity, promoting the exploration of synergistic effects between these mechanisms.

Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake

Preclinical models demonstrate survodutide’s potential to influence hepatic lipid metabolism and reduce adiposity in non-human test subjects, offering valuable insights into its role in studying metabolic adaptations. Survodutide’s extended half-life and pharmacokinetic stability support sustained receptor engagement, making it a versatile candidate for prolonged metabolic research.

This compound continues to provide foundational data for understanding the interplay between glucagon receptor activation and broader metabolic regulation, with applications limited exclusively to experimental research settings involving non-human subjects.

Survodutide is dual-receptor co-agonist peptide studied in non-human research subjects for its effects offering insights into metabolic pathways and adiposity modulation in laboratory settings.